A vaccine which could “revolutionise” tuberculosis treatment has been unveiled by researchers.
It is hoped the vaccine will provide long-term protection against the disease, which kills 1.5 million people around the world each year.
The highly contagious disease is caused by bacteria, and the current vaccine, the BCG jab, is not very effective.
However, while initial trials have proved successful, the vaccine is still a few years away from being licensed.
The team of researchers, who come from all over the world, revealed the vaccine, which is made up of proteins from bacteria which trigger an immune response, during a global summit on lung health in the southern Indian city of Hyderabad on Tuesday.
It has already cleared a critical phase of clinical trials and been tested on more than 3,500 adults in TB endemic regions of South Africa, Kenya and Zambia, researchers said.
